In Alzheimer’s Disease, Six-Month Treatment with GLP-1 Analogue Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

In Alzheimer’s Disease, Six-Month Treatment with GLP-1 Analogue Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

In animal models, the incretin hormone GLP-1 affects Alzheimer’s disease (AD). We hypothesized that treatment with GLP-1 or an analogue of GLP-1 would prevent accumulation of Aβ and raise, or prevent decline of, glucose metabolism (CMRglc) in AD.In this 26-week trial, we randomized 38 patients with...

Full description

Bibliographic Details
Main Authors: Michael eGejl, Albert eGjedde, Lærke eEgefjord, Arne eMøller, Søren B Hansen, Kim eVang, Anders Bertil Rodell, Hans eBraendgaard, Hanne eGottrup, Anna eSchacht, Niels eMøller, Birgitte eBrock, Jørgen eRungby
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-05-01
Series:Frontiers in Aging Neuroscience
Subjects:
Amyloid
Alzheimer’s disease
Glucagon-like peptide-1
liraglutide
cerebral glucose metabolism
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00108/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fnagi.2016.00108/full

Similar Items